Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
BUSINESS
Sumitomo Dainippon Beats 1st Half Guidance, Ups Full-Year Outlook
Sumitomo Dainippon Pharma enjoyed higher profits on higher sales in the first six months of the business year through March, helped by strong sales of mainstay products in Japan and North America, prompting the company to lift its annual forecast.…
To read the full story
Related Article
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
November 1, 2017
- Sumitomo Dainippon Scores Record Earnings on Latuda Boost
May 15, 2017
BUSINESS
- Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
- Ono Picks Up Deciphera in US$2.4 Billion Deal to Extend Pipeline, Market Channels
May 1, 2024
- Celltrion Japan Unveils New List of 5 Biosimilars in Development; Actemra and Pralia and More
May 1, 2024
- PeptiDream, Novartis Expand Peptide Discovery Collaboration
May 1, 2024
- Otsuka’s Q1 Pharma Sales Zoom 16.2% on Global Brands
May 1, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…